SOPHiA GENETICS SA
SOPHSophia Genetics SA is a Swiss-founded data-driven medicine software company with headquarters in Rolle, Switzerland and Boston, Massachusetts, as well as offices in France. It provides genomic and radiomic, and multimodal analysis for hospitals, laboratories, and biopharma institutions.
Drugs in Pipeline
12
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Difluprednate 0.05%
Cataract
Lucentis®
Diabetic Macular Edema
Alleance®
Myopia
PRO-148
Dry Eye
Moxifloxacin / Dexamethasone Ophthalmic Solution
Cataract Extraction
PRO-122
Primary Open Angle Glaucoma
PRO-157
Bacterial Conjunctivitis
Nanodrop®
Dry Eye
PRO-155
Cataract
dorzolamide-timolol-brimonidine
Primary Open Angle Glaucoma
PRO-148 Ophthalmic Solution
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic 0.4% BID
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Difluprednate 0.05% | Phase 3 | Cataract | - | - |
Lucentis® | Phase 3 | Diabetic Macular Edema | - | - |
Alleance® | Phase 3 | Myopia | - | - |
PRO-148 | Phase 3 | Dry Eye | - | - |
Moxifloxacin / Dexamethasone Ophthalmic Solution | Phase 3 | Cataract Extraction | - | - |
PRO-122 | Phase 3 | Primary Open Angle Glaucoma | - | - |
PRO-157 | Phase 2 | Bacterial Conjunctivitis | - | - |
Nanodrop® | Phase 2 | Dry Eye | - | - |
PRO-155 | Phase 2 | Cataract | - | - |
dorzolamide-timolol-brimonidine | Phase 2 | Primary Open Angle Glaucoma | - | - |
PRO-148 Ophthalmic Solution | Phase 2 | Dry Eye Syndrome | - | - |
Sodium Hyaluronate Ophthalmic 0.4% BID | Phase 2 | Dry Eye | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SOPHiA GENETICS SA's drug pipeline?→
CatalystAlert tracks 12 drug candidates in SOPHiA GENETICS SA's (SOPH) pipeline across Phase 3, Phase 2. Its lead program is Difluprednate 0.05% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SOPHiA GENETICS SA's next FDA catalyst?→
SOPHiA GENETICS SA's (SOPH) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SOPH biotech catalysts?→
Add SOPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SOPHiA GENETICS SA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.